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Of more than 155,000 PubMed citations found with the search 
term “placebo,” only ~9,000 (5.8%) included the terms “chil-
dren” or “adolescents.” When all these papers were screened, 
only ~2,000 of them investigated the placebo effect per se, 
and of those, only ~50 (2.5%) discussed the placebo effect in 
children and adolescents. In this narrative review, we explore 
four aspects of the placebo response in children and adoles-
cents: (i) the legal and ethical limitations and restrictions for the 
inclusion of children in clinical trials as well as in experimen-
tal (placebo) research that may explain the poor knowledge 
base; (ii) the question of whether or not the placebo effect is 
larger in children and adolescents as compared with adults; 
(iii) whether the mechanisms underlying the placebo effect are 
similar between children and adults; and (iv) whether media-
tors and moderators of the placebo effect are comparable 
between children and adults. We finally discuss some of the 
consequences from the current placebo research in adults that 
may affect both experimental and clinical research in children 
and adolescents.
Little is known about placebo effects in children, and the majority of this knowledge derives from review articles and 
reanalyses and meta-analyses of clinical trials over the past 
20 y, especially in the areas of attention-deficit hyperactivity 
disorder (ADHD), depression, and migraine. To our knowl-
edge, only a few experimental studies exist that investigated 
the placebo effect and its mechanisms per se in children and 
adolescents. Furthermore, there is little knowledge about pla-
cebo effects in children younger than 6 y.
Of more than 155,000 PubMed citations with the term “pla-
cebo,” only ~9,000 (5.8%) included the search terms “children” 
or “adolescents.” When all these papers were screened, only 
~2,000 discussed the placebo effects per se (1), and of those, 
only ~50 (2.5%) investigated the placebo response in children 
and adolescents.
Placebo research has gained momentum in recent years with 
respect to its underlying neurophysiological and psychobio-
logical mechanisms (2) as well as with respect to its clinical rel-
evance in drug trials and clinical routine (3). However, a num-
ber of issues have remained unsolved, among which are the 
effects of age (4), gender differences (5), and the contribution 
of genetic and psychological profiles. It still is an unsolved puz-
zle whether placebo responders may be reliably distinguished 
from placebo nonresponders (6), and this applies not only to 
the adult population but also to children and adolescents.
In this narrative review, we discuss four aspects of the placebo 
response in children and adolescents: (i) The legal and ethical 
limitations and restrictions for the inclusion of children in clini-
cal and experimental trials that may explain the currently poor 
knowledge base; (ii) the question of whether or not the placebo 
response is larger in children and adolescents as compared with 
adults; (iii) whether the mechanisms of the placebo response 
allow a comparison of children and adults; and (iv) whether 
mediators and moderators of the placebo response are simi-
lar or different between children and adults. We finally discuss 
some of the consequences from the current placebo research in 
adults, which may affect both experimental and clinical research 
in children and adolescents, and future research possibilities.
LEGAL AND ETHICAL CONSIDERATIONS FOR THE 
INCLUSION OF CHILDREN IN CLINICAL TRIALS
Current legal and ethical rules for the inclusion of children into 
randomized, double-blinded, and placebo-controlled trials are 
far from being clear and are to some degree even contradictory.
Guidelines of the US National Institutes of Health (7), the 
US Food and Drug Administration (8), and the European 
Medicines Agency (9) explicitly call for the need to include 
children into the testing of novel compounds as long as no 
specific reasons argue against it (10,11), as drugs should not 
be used in children without such tests and their use should not 
merely be based on dose adjustments from doses for adults, 
e.g., based on body weight.
In contrast to the policy of drug approval authorities, the 
Declaration of Helsinki of the World Medical Association in its 
current version (as of 2008) (12) does not explicitly mention chil-
dren but includes them among all “incompetent” persons who 
are not to be included in placebo-controlled trials unless impor-
tant reasons argue in favor of such inclusion, e.g., no adequate 
medication is available that is approved for use in adults (13).
Common to both sets of rules is that children can only be 
included in trials after careful consideration of the risks and 
benefits (14).
Further ethical principles are the protection of “integrity, 
right to self-determination, privacy, and confidentiality of 
personal information of research subjects” (p. 2) (12). In adult 
or competent persons, these requirements are fulfilled by the 
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process of informed consent that particularly includes ade-
quate information about the study aims and methods, storage 
of personal information, voluntariness of participation, and 
the right to refuse participation at any time. For incompe-
tent persons, this informed consent must be given by a legally 
authorized representative, but if they are able to agree, their 
decision must be taken into consideration (12). For the inclu-
sion of children, these requirements imply specific burden: 
physicians and parents have to decide at which age or cogni-
tive developmental stage children are able to agree or disagree 
to study participation, and information must be designed in a 
written or verbal way they are able to understand. For example, 
in the case of randomized placebo-controlled trials, children 
have to understand that they could be assigned to take pills 
without any active medication.
According to the Declaration, not only children but also 
adults are only to be exposed to placebo treatment in case other 
adequate treatment options are not available (12). By contrast, 
the World Medical Association Declaration of Helsinki favors 
the position that novel compounds can only be tested against 
the best medical therapy currently available (comparative 
effectiveness research), and thus calls for more “comparator 
trials” in which new drugs are tested for their noninferiority in 
comparison with other and available treatment options (15). 
However, as has been shown (16), the likelihood of receiv-
ing active treatment may determine the size of the placebo 
response, with higher placebo response rates when the chances 
of active treatment increase above 50%. Whether this is also 
the case in children is unknown and needs to be determined.
In this respect, comparator trials (or comparative effective-
ness research) induce a 100% chance for active treatment and 
thereby generate a substantially and significantly higher pla-
cebo response and a poorer discrimination between drug and 
placebo than do placebo-controlled trials (17), thus creating 
an interesting ethical dilemma (18): Although they attempt 
to minimize the number of patients who are withheld from 
being adequately treated, they in fact require more patients to 
be included in the trial for statistical testing of drug efficacy 
(noninferiority). This would create specific burden to studies 
in children and adolescents if—as we will discuss below—their 
placebo response rate would differ from that of adults.
ARE PLACEBO RESPONSES DIFFERENT BETWEEN CHILDREN 
AND ADULTS?
Reviews and meta-analyses usually conclude that the placebo 
response rates in trials in general are higher in children and 
adolescents than in adults but that the drug responses are 
equal among them (see below). In consequence of this, drug 
effects cannot be calculated in children on the basis of data 
generated with adults, as stated above. This also implies that 
more children have to be included in drug trials to achieve the 
same degree of security of drug efficacy as in adults. However, 
only very few reviews and meta-analyses directly compared 
placebo effects in children, adolescents, and adults, and only 
indirect comparisons of separate studies in these populations 
are possible for most conditions.
In a meta-analysis of randomized and placebo-controlled 
treatment trials in pediatric major depression, Bridge et al. 
(19) found that—with the exception of one treatment trial 
with a selective serotonin reuptake inhibitor (20)—the pla-
cebo response was significantly higher in children younger 
than 12 years (54.3%) as compared with children older than 
12 years (44.9%), whereas the drug response was similar (58.4 
and 61.5%, respectively). By contrast, meta-analytic data from 
studies in adults using similar drugs and end points revealed 
an average placebo response rate of 34.7% (17).
A similar result was found by Rheims et al. (21) with respect 
to treatment studies for epilepsy: children had a significantly 
higher placebo response rate in comparison with adults (19.0 
vs. 9.9%), whereas the efficacy of the medication was not statis-
tically different between the two groups (37.2 vs. 30.4%).
A systematic review on oral triptanes in the treatment of 
acute migraine headache revealed that the only two studies 
between 1991 and 2002 that reported results in children and 
adolescents showed on average a significantly higher response 
rate (48.5%) and number of pain-free patients (25.5%) 2 h 
after placebo intake in comparison with adults (28.9 and 6.1%, 
respectively) (22).
A review of drug treatment in ADHD in children reported 
mean placebo response rates of 20–30% in children (23), and a 
comparable review in adults noted a 10% response with placebo 
(24). The guidelines for ADHD treatment in adults list studies 
with a placebo response ranging between 0 and 17% (25).
In an editorial for a study by Saps et al. (26), Benninga and 
Mayer (27) quoted lower placebo response rates in adults with 
pain-related functional gastrointestinal disorders. Saps et al. 
(26) detected no difference in the effectiveness of amitripty-
line, a tricyclic antidepressant, (63.0%) and placebo (57.5%) in 
the treatment of pediatric pain-related functional gastrointes-
tinal disorders and pointed toward the fact that in comparable 
studies among adults, placebo response rates were substan-
tially lower and in the range of 40% across many trials (28).
In a systematic review of placebo response rates in chil-
dren with psychiatric conditions (major depression disor-
der, obsessive–compulsive disorder, and nonobsessive–com-
pulsive disorder anxiety disorders), Cohen et al. (29) noted 
higher placebo response rates in children than in adolescents, 
although these differences were not statistically significant. 
Furthermore, these and the pooled response rates are higher 
than those known for adults with similar conditions (Table 1). 
Table 1. Placebo response rates in children, adolescents, and adults 
with psychiatric disorders
MDD (%) OCD (%) AD (%) References
Children 60 40 42 29
Adolescents 49 32 32 29
Pooled 50 31 40 29
Adults 38 23 33 17,82,83
“Pooled” refers to the pooling of data for children and adolescents in ref. 29.
aD, anxiety disorders without OcD; MDD, major depression disorder;  
OcD, obsessive–compulsive disorder.
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Examples of psychiatric and nonpsychiatric trials are reviewed 
in a recent paper by Parellada et al. (30).
In addition, the frequent use of homeopathy in children 
(31)—beyond the question of whether homeopathy is placebo 
treatment per se (32)—and placebo response rates in food 
challenges (33) argue in favor of higher placebo responses in 
children as compared with adults.
By contrast, only one review-type article reports no age 
effects on the placebo response size in clinical studies in 
migraine headache (34).
Taken together, these reports strongly imply that age is nega-
tively correlated with the size of the placebo response.
ARE THE MECHANISMS UNDERLYING THE PLACEBO EFFECT 
SIMILAR BETWEEN CHILDREN AND ADULTS?
It is assumed that the placebo response is mainly generated 
by two distinct mechanisms: expectancies on one hand and 
Pavlovian conditioning on the other (2,3). A similar assump-
tion has been proposed for children and adolescents (35), but 
the possibility that further mechanisms, such as instrumental 
learning (36) or learning by imitation (37), exist cannot be 
excluded. Furthermore, the contribution of genetic factors is 
likely but has only been shown in a few studies with adults so 
far (38–40).
Beyond associative learning (Pavlovian conditioning and 
instrumental learning), children could probably be susceptible 
to learning by imitation and role models. In an experimental 
setup, Colloca and Benedetti (37) compared three groups of 
(adult) volunteers in a pain experiment in which painful cuta-
neous stimuli were announced following a red signal light, 
whereas a green light would indicate nonpainful stimuli; in 
all cases, the stimuli were equal in intensity. In one subgroup, 
subjects could observe another volunteer during performance 
before being tested; in a second group, they were exposed to 
a Pavlovian conditioning procedure; and in a third group, the 
cognitive expectancy of stimulus intensity was manipulated. 
Results showed conditioning and imitation learning to be 
equally effective (43.4 and 39.2% pain reduction) as compared 
with expectancy alone (8.4%).
One could speculate that given higher learning capacities in 
children (aged 6 y and older) as compared with adults, at least 
for associative learning, children would exhibit higher placebo 
responses in clinical trials. Surprisingly, direct comparison 
of the effect size of associative learning, e.g., with anticipa-
tory nausea during chemotherapy, has never been performed, 
despite the fact that both children and adults have been shown 
to be affected (41) and to be responsive to behavioral coun-
termeasures based on such learning, e.g., latent inhibition and 
overshadowing (42).
Similar assumed mechanisms generate the question of why 
placebo effects should be higher in children as compared with 
adults. Among the offered explanations are not only higher 
expectations of parents and their respective behaviors (23,27) 
but also the increased attention of the media (43). This may—
via increased parents’ attention—lead to higher expectations 
of children, and parents may direct their attention toward 
symptom improvement (23). It is speculative but likely that 
the “regression to the mean” effect may be larger in studies of 
children because parents may exaggerate their children’s symp-
toms at the time of recruitment to make sure their children are 
included (21). In contrast to adults, children tend to assume 
more often to be included in the medication arm rather than in 
the placebo arm of the study (44) and apparent unblinding of 
studies due to parents’ observation of their children’s behavior 
appears to be frequent (45).
A recent meta-analysis of 31 depression trials in children 
and adolescents (46) contradicts some of these assumptions. 
They found that despite higher placebo response rates in chil-
dren, they cannot be attributed to most of the factors that 
have been found responsible for high placebo response rates 
in adults, e.g., the amount of contact with medical staff or the 
chances of receiving active treatment. In placebo-controlled 
trials, however, placebo responses significantly increase with 
the amount of therapeutic contact in adolescent but not in 
younger patients. The authors conclude that whereas patient 
expectancy strongly influences response rates to medication 
and placebo in depressed adults, it appears to be less important 
in the treatment of children with depression. Attempts to limit 
placebo response and improve the efficiency of antidepressant 
trials for pediatric depression should focus on other causes 
of placebo response apart from expectancy (46). This seems 
traceable because younger children may not deal with abstract 
expressions such as “probability” or “placebo.”
By contrast, a meta-analysis by Evers et al. (34) identified 8 
crossover and 11 parallel-group trials on acute treatment of 
migraine headache in which the placebo response rates were 
considerably lower in crossover trials than in parallel-group 
trials (19.2 vs. 27.1% for the end point “pain free” after 2 h 
and 39.4 vs. 56.9% for “pain relief ” after 2 h). Whereas cross-
over trials provide a 100% chance for every patient to receive 
placebo treatment, in parallel-group trials, the chance to 
receive inactive treatment depends on the number of study 
groups but is not higher than 50% when there is at least one 
active medication group. Therefore, the results are compa-
rable with findings from an older meta-analysis of migraine 
treatments in adults by Diener et al. (47) that reported 
increasing placebo response rates with increasing likeli-
hood of receiving active treatment. Taken together, these 
results could indirectly imply an awareness of expressions 
such as “probability” and “placebo” in studies with children 
too, although it cannot be excluded that it depends more 
on reactions of parents as stated above. However, crossover 
trials—although they also provide a 100% chance of receiv-
ing active treatment—have another pitfall that may corrupt 
proper estimation of drug and placebo effects: patients who 
receive the drug first and then the placebo may show higher 
placebo response rates (due to conditioned drug effects from 
the first treatment phase) (48) than those who receive the 
placebo first and then the drug—the latter may “profit” from 
the natural course of disease that frequently occurs in acute 
medical conditions (49) but is incorrectly attributed to the 
drug effect.
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ARE THE MEDIATORS AND MODERATORS OF THE PLACEBO 
EFFECT SIMILAR BETWEEN CHILDREN AND ADULTS?
Although age appears to be a relevant moderator of the pla-
cebo response (as discussed above), gender differences in 
adults were occasionally investigated, but results are generally 
not consistent (5,50,51). However, experimental studies on 
placebo analgesia usually reveal higher placebo response rates 
in male adults (52). To our knowledge, there are only two arti-
cles that report analyses of gender differences in the placebo 
response in children: the review by Evers et al. (34) found no 
gender differences, whereas the other review (53), also focus-
ing on migraine headache, found higher placebo response 
rates in girls (66.7%) as compared with boys (43.3%).
Among the many personality characteristics that have been 
tested for predicting placebo response in clinical and experi-
mental trials, only a few have gained more than incidental 
importance, and many more may never have been reported 
due to missing predictive value. Hypnotic and other suggest-
ibility (54), dispositional optimism (55), the locus of control 
(56), negative emotions such as fear and anxiety (57), and 
other psychometric characteristics have never been tested 
with respect to placebo responses in children and adolescents. 
However, it is well established that personality, coping char-
acteristics, and outcome expectancies (e.g., negative expectan-
cies, low self-efficacy, and locus of control) codetermine health 
behavior (58) and outcome of interventions (59) in a rather 
complex manner in chronic conditions. It is thus likely that 
similar effects of these personality characteristics determine 
positive treatment outcomes also with “placebo” interventions 
in adults, adolescents, and children.
Other reviews that have attempted to identify differences 
between responders and nonresponders, such as the review by 
Newcorn et al. (60), reported higher placebo response rates in 
children with ADHD when they were easy to distract, had not 
had stimulating medication before, presented with comorbid 
tics, and were of non-Caucasian origin. Cohen et al. (61) iden-
tified a Caucasian origin, the duration of the disorder, its sever-
ity at onset, and the result of treatment as predictors of a non-
response to placebo in psychotropic medication trials in major 
depression, anxiety, and compulsive behavior. In a reanalysis 
of data of the placebo arm of a lithium trial in aggressive chil-
dren with behavioral problems, Sanchez et al. (62) found that 
placebo responders more often grew up in families with a high 
aggression potential, e.g., with parents having a criminal back-
ground, and lower placebo response rates were associated with 
milder ADHD symptoms.
These findings point toward another factor that would need 
exploration for placebo research in children: studies have 
shown that parents’ beliefs and their stress levels largely affect 
physical and psychological functioning in children (63) and 
adolescents (64). The same moderators will likely operate in 
pediatric clinical trials and will determine the success and fail-
ure of medical interventions. If so, they may as well explain 
why moderators effective in the placebo response in adults, 
e.g., the amount of professional attention a patient receives (see 
above) are not operating or not operating as well in children 
(46), and other moderators may be more effective that have not 
been identified in adults in respective meta-analyses.
It has been argued (65) that placebos could operate by pro-
ducing changes in how caregivers perceive children’s symptom 
changes. Placebos could also operate by producing changes in 
how caregivers behave toward children, which in turn produce 
behavioral changes in the child. This concept of “placebo by 
proxy” has recently received attention both from a method-
ological point of view (66) and in an observational study on 
temper tantrums in children (67).
Grelotti and Kaptchuk (66) argued that the expectations of 
a patient toward his/her treatment are not only based on his/
her own experience and hopes but also occur in a social con-
text, in which proxies (family members, caregivers, and rela-
tives) respond to symptoms and their improvement as well 
as their worsening. Because these can exist independently of 
any placebo response of the patient, their contribution to the 
patient’s response are largely unknown and uninvestigated. 
One of the paradigmatic examples the authors cite refers to 
the fact that antibiotics are frequently overprescribed spe-
cifically in children because of parents’ concerns and wishes 
(68). Proxies’ influences on (placebo) responsiveness may 
also be responsible for differences in efficacy reports seen 
between doctor and patient-reported outcomes, especially in 
depression (69).
Whalley and Hyland (67) take the argument that placebo 
by proxy may play an important role especially in children 
one step further: they investigated whether the efficacy of an 
impure placebo (Bach flower therapy, a homeopathic rem-
edy) to improve symptoms of temper tantrums in 2–5-y-old 
children would be affected by the parents’ beliefs and moods. 
To exclude any direct effect of physician–child and physician–
parent interaction, an automated telephone system was used 
for symptom recording. The authors found a sustained and sig-
nificant improvement of tantrum frequency and severity that 
was strongly correlated to parents’ mood. Because this was an 
observational study, the authors were not able to conclude the 
true nature of the symptomatic improvement but assumed that 
these are “pure” placebo effects. Whether symptom improve-
ments were mirrored in children’s behavioral changes or only 
in parents’ perception cannot be concluded from the data.
WHAT ARE THE CONSEQUENCES FOR CLINICAL AND 
EXPERIMENTAL STUDIES AND FUTURE RESEARCH?
Evidently, if placebo response rates in clinical trials with chil-
dren are higher than the response rates of adults with similar 
or other drugs/interventions in similar clinical conditions and 
across many diseases, then extrapolating drug efficacy in chil-
dren from respective studies in adults runs the risk of underes-
timating the placebo response and overestimating drug efficacy. 
An apparent immediate consequence of this would be the need 
to conduct specific pediatric trials and to increase the num-
ber of pediatric patients in such randomized controlled trials 
(as compared with the number of patients in adult trials) to 
achieve “significance” of the data—this would create a similar 
ethical paradox as the one discussed above with comparative 
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effectiveness research trials (18) and hence is not feasible in 
pediatric trials. As stated above, inclusion of children and 
adolescents as incompetent but self-determined persons (12) 
requires specific considerations that influence study designs. 
Whether adapted study designs from adult patients may affect 
study outcomes in children and adolescents is unknown.
We have recently proposed (70) that minimizing the pla-
cebo response rate in randomized controlled trials is but one 
strategy to gain insight into drug efficacy on the one hand 
and into mechanisms behind the placebo response on the 
other. Factors that influence drug–placebo differences can 
be derived from studies that examine placebo response pre-
dictors, but an ideal study design has not yet been found. 
For example, drug–placebo differences can be best detected 
in studies with a 50% chance to receive drug or placebo (16), 
but as discussed above, there are ethical limitations for such 
study designs not only in adults but also specifically in chil-
dren and adolescents.
By contrast, maximizing the placebo response (in compar-
ison with a standard “treatment as usual” or a no-treatment 
control group) may be a better way to use the placebo mecha-
nisms (70), especially in children and adolescents. Two recent 
examples of conditioning from the published literature may 
illustrate such a strategy: preconditioning drug effects during 
an initial run-in phase (Table 2) was shown to reduce subse-
quent drug dosing by up to 50% in an adult trial of cortico-
steroid therapy in psoriasis (71) and in medication therapy of 
children with ADHD (72). Another possibility to harness the 
placebo effect could be to optimize expectations of patients 
(73): In adults, verbal instructions may shape expectations that 
decrease (or increase) sensations of itch and pain (74) or reveal 
placebo analgesia by reducing anxiety (57) not only in healthy 
volunteers but also in patients with irritable bowel syndrome 
(75). One of the rare experimental studies in children and ado-
lescents also revealed effects of verbal instructions on needle 
pain from venipuncture (76). Furthermore, warm empathic 
interactions between practitioners and patients have been 
shown to evoke significant placebo effects in adult patients 
with irritable bowel syndrome (50). Therefore, the effects of 
expectations and of patient–practitioner interactions on symp-
toms in children and adolescents, as well as their mediation by 
parents, should be further investigated.
Using placebo mechanisms in daily practice implies ethi-
cal considerations such as required informed consent (73). 
However, research groups have also demonstrated efficacy of 
an open-label placebo intervention in ADHD (77) similar to a 
trial in adult patients with irritable bowel syndrome (78).
In summary, more experimental research is needed for the 
assessment of placebo responses and mechanisms as well as 
for other and alternative study designs in children and adoles-
cents. Future research could be based on results from experi-
mental and clinical studies in adults, e.g., on effects of con-
ditioning and expectations, but should take into account that 
mechanisms, moderators, and mediators in children and ado-
lescents may be different from those of adults. Furthermore, 
reviews and meta-analyses on placebo effects in adults showed 
that the susceptibility to placebo mechanisms varies among 
symptoms, conditions, and diseases (3), but comparisons with 
children and adolescents are missing. Designs that have been 
proposed for adults (79) need to be explored for the younger 
ones as well. Among them, the recently proposed “free-choice 
paradigm” (80) may be specifically suitable for children, as it 
avoids many ethical concerns and favors simple and child-
adequate choice behavior rather than symptom improvement 
as an outcome measure. The example by Whalley and Hyland 
(67) illustrates that it will also be feasible to separate placebo 
effects of the patient from those of proxies.
SUMMARY AND CONCLUSION
The few available data on placebo response rates in children 
and adolescents as compared with adults allow only pre-
liminary conclusions: response rates appear to be higher in 
children and adolescents than in adults, and the underlying 
mechanisms, such as expectancy and conditioning, appear to 
be the same in all the age groups. However, in light of the 
reported (46) lower efficacy of expectancy factors, such as the 
amount of physician contact time during trial, (Pavlovian) 
conditioning and other learning mechanisms may play a 
greater role in generating placebo responses in children as 
compared with adults. As has also been shown in adults, 
the balance between expectancy and learning mechanisms 
may vary substantially, e.g., between genders (81), and may 
account for apparently similar placebo response rates, despite 
the different mechanisms that have generated them. In addi-
tion, the role of placebo by proxy needs further exploration, 
and specific trial designs for children and adolescents need to 
be developed. It also needs to be shown whether learning and 
conditioning plays a greater role in the placebo response in 
children and adolescents as compared with adults.
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Table 2. Principle of conditioning of drug effects with partial reinforcement
Acquisition period Maintenance treatment
Day of treatment Day of treatment
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
D D D D D D D D D D D D D D P P D D P D P D D P P D D
This example shows a drug application regime with a 2-wk acquisition period, followed by drug applications with interspersed placebos (likelihood of placebo application in week 3 
and 4: 0.50) (modified with permission from ref. 3).
D, drug; P, placebo.
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